Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 clazakizumab trial in chronic active antibody-mediated rejection after kidney transplant
NL-OMON54769Phase 3Completed
- Sponsor
- -
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of clazakizumab in Chronic humoral rejection (cABMR). Primary endpoints: All-cause composite allograft loss or irreversible loss of allograft function due to CABMR, Progressive loss of kidney function and 1 more. Started Jul 2021; status: completed.
02
Drugs
clazakizumab
03
Conditions
Chronic humoral rejection (cABMR)
Beyond the preview
Go deeper on NL-OMON54769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54769.